Phibro Animal Health Corp PAHC and Dyadic International Inc DYAI have entered into an exclusive license agreement for a Phibro targeted disease.
- Dyadic granted Phibro an exclusive license for its proprietary C1 -cell protein production platform to produce specific targeted antigens for developing and commercializing a poultry vaccine for a Phibro targeted disease.
- The parties will continue developing a vaccine candidate using Dyadic's C1 cells.
- Phibro Earnings: Phibro posted Q2 FY22 sales of $232.7 million, +13% Y/Y, beating the consensus of $217.14 million.
- Adjusted EPS increased 9% to $0.37, surpassing the consensus of $0.33.
- The gross margin decreased 270 basis points to 30.4%. Adjusted EBITDA reached $29.1 million.
- Guidance: Phibro revised its FY22 sales to $890 million – $920 million, up from $860 – $890 million.
- It Raised adjusted EPS guidance to $1.30 - $1.39, from $1.25 –$1.32.
- The Company expects adjusted EBITDA of approximately $110.0 – $114.0 million.
- Price Action: DYAI stock is down 0.25% at $4.03, and PAHC shares are up 5.59% at $19.70 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechEarningsNewsPenny StocksGuidanceHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in